02.05.2016 Views

Final Program

4njPuP

4njPuP

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

32 SUNDAY • MAY 15<br />

Target Audience<br />

Clinicians, researchers and educators with an interest in lung cancer and in<br />

global lung health.<br />

Objectives<br />

At the conclusion of this session, the participant will be able to:<br />

• learn new findings about best practices for early detection of lung cancer;<br />

• apply recent guidelines and policy statements to be able to better diagnose<br />

and stage lung cancer;<br />

• integrate new treatment and prevention options in discussing lung cancer<br />

with patients.<br />

Lung cancer is the leading cause of cancer death in the world. The challenge to<br />

decrease lung cancer mortality through prevention, early detection, rapid<br />

diagnosis, staging, and precision therapy is global; yet approaches to these<br />

efforts vary. Speakers for this session are drawn from the International<br />

Relations Working Group of the ATS Thoracic Oncology Assembly with leaders<br />

from ATS, JRS, ERS, the Chinese Respiratory Association, and the Latin<br />

American Thoracic Association. Topics will include prevention, lung cancer<br />

screening, precision therapy, updates in lung cancer classification and staging,<br />

and quality benchmarks for diagnosis and treatment.<br />

Chairing: C.A. Powell, MD, New York, NY<br />

M. Gaga, MD, PhD, Athens, Greece<br />

S. Quadrelli, MD, PhD, Buenos Aires, Argentina<br />

C. Bai, MD, PhD, Shanghai, China<br />

9:00 The Role of Smoking Cessation in the Prevention of Lung<br />

Cancer<br />

J.M. Samet, MD, MS, Los Angeles, CA<br />

9:20 WHO-IARC, IASLC-ATS Updates of Lung Cancer Classification,<br />

C.A. Powell, MD, New York, NY<br />

9:40 Integration of Imaging and Molecular Biomarkers for Lung<br />

Cancer Detection<br />

C. Bai, MD, PhD, Shanghai, China<br />

10:00 Screening for Lung Cancer: Maximizing Benefits and<br />

Minimizing Harms<br />

M.K. Gould, MD, MS, Pasadena, CA<br />

10:20 Precision Therapy of Lung Cancer: Targets, Resistance, and<br />

Opportunities<br />

K. Kiura, MD, PhD, Okayama, Japan<br />

10:40 European Initiative for Quality Management in Lung Cancer<br />

Care<br />

M. Gaga, MD, PhD, Athens, Greece<br />

This session and the International Conference are supported by an educational grant from<br />

AstraZeneca LP.<br />

All CME sessions have been planned and implemented in accordance with the Essential<br />

Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)<br />

and are free of the control of commercial interests<br />

A12<br />

BASIC • CLINICAL • TRANSLATIONAL<br />

SCIENTIFIC SYMPOSIUM<br />

CME Credits Available: 2.0<br />

ENTREPRENEURSHIP: EMBRACING THE<br />

INNOVATIVE ENVIRONMENT - FROM BENCH TO<br />

BOARDROOM TO BEDSIDE<br />

Drug and Device Discovery Development Committee<br />

9:00 a.m. - 11:00 a.m. MOSCONE CENTER<br />

Room 3010/3012 (West Building, Level 3)<br />

Target Audience<br />

Basic,translational and clinical investigators and those responsible for<br />

translating knowledge into innovations in academia, government, nonprofits<br />

and industry.<br />

Objectives<br />

At the conclusion of this session, the participant will be able to:<br />

• understand how to turn discoveries into innovations;<br />

• find funding sources for innovations;<br />

• grow one’s career.<br />

The symposium will show the importance of entrepreneurship in creating an<br />

innovative environment. The session will focus on successful examples of<br />

entrepreneurship and innovation in big pharma, academia, biotech and<br />

government. Speakers will discuss different entrepreneurial mechanisms<br />

currently used to identify and fund innovation, including venture capital,<br />

philanthropy, patient support organizations and government (e.g., NIH, NSF)<br />

Small Business Innovation Research/Small Business Technology Transfer<br />

(SBIR/STTR), and their applicability to a diverse ATS membership. Regulatory<br />

insights will be provided into alternative pathways to develop and secure<br />

approval for innovative drugs and devices.<br />

Chairing: T.F. Reiss, MD, New Hope, PA<br />

J. Moss, MD, PhD, Bethesda, MD<br />

9:00 The Innovative Mindset<br />

M. Turner, PhD, Westfield, NJ<br />

9:24 Entrepreneurship: Academic Insights into Technology<br />

Transfer<br />

C. Wyskiel, MBA, Baltimore, MD<br />

9:48 Early Lessons in Entrepreneurship: A Venture Capital<br />

Perspective<br />

C. Berkland, PhD, Lawrence, KS<br />

10:12 SBIR/STTR Grants: Funding the Path from Academia to<br />

Industry<br />

C.G. Irvin, PhD, Burlington, VT<br />

10:36 The Cystic Fibrosis Foundation: A Profitable Non-Profit’s<br />

Guide to Therapeutic Success<br />

R.J. Beall, PhD, Bethesda, MD<br />

ATS 2016 • San Francisco

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!